Shasun Pharmaceuticals has completed both USFDA and Mexican Cofepris (Mexican regulatory authority) inspection at its API facility at Cussalore Tamil Nadu, India.

The USFDA audit was held on second week of June 2014 and the Mexican Cofepris audit by APIF was held during the last week of June 2014.

On completion of the inspection the USFDA inspectors concluded that the facility, systems and practices comply with USFDA requirements with minor 483 and on completion of the inspection APIF concluded that Shasun's compliance with current good manufacturing practices (cGMP) are fully met and a formal GMP certificate will be issued by Cofepris in due course.

Shares of the company gained Rs 18.65, or 11.14%, to trade at Rs 188 at the BSE (11.47 a.m., Tuesday).